Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study

Barzegar, Mahdi; Manteghinejad, Amirreza; Afshari-Safavi, Alireza; Mirmosayyeb, Omid; Nasirian, Maryam; Bagherieh, Sara; Mazaheri, Shahrbanoo; Rahimi, Maryam; Zabeti, Aram; Javanmard, Shaghayegh Haghjooy; Shaygannejad, Vahid

doi:10.1016/j.msard.2023.104548

Cited by 2 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to this study, vaccination provided a significant protective effect against hospitalization. The effectiveness of vaccination against COVID-19 in the prevention of severe disease in PwMS has been previously observed in various studies [51,52], although certain DMTs seem to reduce the effectiveness of vaccines. Since immunization with SARS -CoV-2 vaccines has been proven to be safe in PwMS [53,54], and the development of severe disease may trigger inflammatory activity and clinical deterioration of their neurological symptoms [13,52,55,56], vaccination against COVID-19 disease is recommended [35,37,38].…”

Section: Discussionmentioning

confidence: 74%

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece

Bakirtzis,

Konstantinidou,

Stavropoulou De Lorenzo

et al. 2023

JCM

View full text Add to dashboard Cite

Over the past three years, humanity faced the abrupt spread of COVID-19, responsible for a worldwide health crisis. Initially, it was believed that individuals with chronic disorders, including multiple sclerosis, were more likely to be infected and suffer a worse degree of COVID-19 disease. Therefore, data with regard to COVID-19 disease outcomes in these populations may provide additional insight with regard to the management of chronic diseases during viral pandemics. The objective of this study is to evaluate COVID-19 disease course in people with multiple sclerosis (PwMS) during the COVID-19 pandemic in Greece and explore the impact of vaccination in the outcome of SARS-CoV-2 infection in this population. Anonymized data, extracted from nationwide administrative records between February 2020 and December 2021, were retrospectively analyzed in order to identify PwMS with SARS-CoV-2 infection. Demographic data, as well as data regarding COVID-19 infection and vaccination, were additionally collected. The study sample included 2351 PwMS (65.1% females, 51.2% unvaccinated at the time of infection). A total of 260 PwMS were hospitalized, while 25 PwMS died from COVID-19 disease and its complications. Older age, male sex and the presence of comorbidities were independently associated with a higher probability of hospitalization. The risk of hospitalization was decreased in PwMS receiving some disease-modifying treatments. Anti-CD20s demonstrated high odds ratios without reaching statistical significance. Regarding fatal outcome, only age reached statistical significance. Vaccination provided a significant protective effect against hospitalization but did not exhibit a statistically significant effect on mortality.

show abstract

Section: Discussionmentioning

confidence: 74%

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece

Bakirtzis,

Konstantinidou,

Stavropoulou De Lorenzo

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…2 As of January 2023, approximately 663 million individuals have been infected with the coronavirus, resulting in 6.7 million deaths. 3 Common symptoms of COVID-19 include fever, cough, fatigue, shortness of breath, muscle pain, chills, sore throat, headache, and chest pain. However, these symptoms are nonspecific and can also be observed in other infections, such as influenza.…”

Section: Introductionmentioning

confidence: 99%

“…COVID‐19, first identified in Wuhan, China, in late December 2019, spread to 213 countries in 2020 and subsequently became a global pandemic 2 . As of January 2023, approximately 663 million individuals have been infected with the coronavirus, resulting in 6.7 million deaths 3 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cq values as an indicator for COVID‐19 outcomes: A study of the correlation between laboratory parameters

Safdari,

Bagheri,

Talkhi

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThe ongoing outbreak of the respiratory disease coronavirus disease 2019 (COVID‐19) is currently presenting a major global health threat. This pandemic is unprecedented in recent human history. The objective of this study was to examine the relationship between cycle quantitation (Cq) and laboratory parameters in COVID‐19 patients, aiming to determine if Cq levels can provide valuable insights into the COVID‐19 disease.MethodsThis study involved 234 participants who were divided into case and control groups. Real‐time PCR tests were used to diagnose COVID‐19 cases in the study participants. Blood tests, including complete blood count, C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), D‐dimer, IgG, and IgM, were also conducted. Statistical analysis was performed using SPSS 22 software.ResultsThe findings showed that COVID‐19‐positive cases had significantly higher levels of the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), D‐dimer, ESR, CRP, and LDH compared to normal cases. Additionally, the case group had significantly lower lymphocyte and platelet counts. There was a statistically significant positive correlation between Cq levels and lymphocyte count (r = .124, p = .014). Conversely, there was a statistically significant inverse correlation between Cq levels and NLR (r = −.208, p = .017). Furthermore, the evaluation of hematological, inflammatory, and biochemical indexes in COVID‐19 patients using the receiver‐operating characteristics curve demonstrated statistically appropriate sensitivity and specificity.ConclusionOur outcomes indicated a significant association between Cq levels and PLR, NLR, D‐dimer, CRP, and ESR in COVID‐19 patients. Consequently, including the report of laboratory parameters alongside Cq values offers a promising prognosis.

show abstract

Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study

Cited by 2 publications

References 54 publications

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece

Cq values as an indicator for COVID‐19 outcomes: A study of the correlation between laboratory parameters

Contact Info

Product

Resources

About